2.
本研究纳入患者疗效评定(n=65)
Efficacy evaluation of patients included in this study (n=65)
| Efficacy | GO group (n =33) | GP group (n =32) | P |
| CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; PFS: progression-free survival; OS: overall survival. | |||
| CR | 0 | 0 | |
| PR | 12 | 13 | |
| SD | 12 | 8 | |
| PD | 9 | 11 | |
| Efficacy | 12 (36.4%) | 13 (40.6%) | 0.801 |
| Clinical stability | 24 (72.7%) | 21 (65.6%) | 0.598 |
| PFS (week) | 24 | 18 | 0.565 |
| OS (week) | 44 | 36 | 0.918 |